Peptide name : P09

Source/Organism : Eukaryotic Translation Elongation Factor 1 Gamma (Eef1G) fragment

Linear/Cyclic : Linear

Chirality : L

Peptide length: 13

C-terminal modification: Linear

N-terminal modification : Free

Non-natural peptide information:

Assay type : MTT assay

Assay time : 48-h

Activity : Relative viability = 1.07 at 50 μg/ml

Cell line : U-2 OS

Cancer type : Bone Cancer

Other activity : Anticancer

Amino acid composition bar chart :

Molecular mass : 1541.6616 Dalton

Aliphatic index : 0.453

Instability index : 11.0538

Hydrophobicity (GRAVY) : -0.846

Isoelectric point : 6.0452

Charge (pH 7) : -0.2033

Aromaticity : 23.07

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 0.8571

hydrophobic moment : 0.659

Missing amino acid : C,D,F,H,I,K,M,Q,S,V

Most occurring amino acid : A

Most occurring amino acid frequency : 2

Least occurring amino acid : G

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (30., 23., 46.)

SMILES Notation: CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)N)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)[C@@H](C)O

1 : Cui CP, et al. Anticancer peptides from induced tumor-suppressing cells for inhibiting osteosarcoma cells. Am J Cancer Res. 2023; 13:4057-4072.

Paper title : Anticancer peptides from induced tumor-suppressing cells for inhibiting osteosarcoma cells.

Doi : https://doi.org/Not available

Abstract : Osteosarcoma (OS) is the most frequent primary bone cancer, which is mainly suffered by children and young adults. While the current surgical treatment combined with chemotherapy is effective for the early stage of OS, advanced OS preferentially metastasizes to the lung and is difficult to treat. Here, we examined the efficacy of ten anti-OS peptide candidates from a trypsin-digested conditioned medium that was derived from the secretome of induced tumor-suppressing cells (iTSCs). Using OS cell lines, the antitumor capabilities of the peptide candidates were evaluated by assaying the alterations in metabolic activities, proliferation, motility, and invasion of OS cells. Among ten candidates, peptide P05 (ADDGRPFPQVIK), a fragment of aldolase A (ALDOA), presented the most potent OS-suppressing capabilities. Its efficacy was additive with standard-of-care chemotherapeutic agents such as cisplatin and doxorubicin, and it downregulated oncoproteins such as epidermal growth factor receptor (EGFR), Snail, and Src in OS cells. Interestingly, P05 did not present inhibitory effects on non-OS skeletal cells such as mesenchymal stem cells and osteoblast cells. Collectively, this study demonstrated that iTSC-derived secretomes may provide a source for identifying anticancer peptides, and P05 may warrant further evaluations for the treatment of OS.